Cancer

Title
The Effects of Trastuzumab on Standard Treatment with Chemotherapy for Early Stage, HER2-low Breast Cancer
Trial Number
203352031611
Number of Participants
3,260
Principal Investigator

Kathy S. Albain

M.D.
Hematology/Oncology
Professor
Eligibility

Women ages > 18 years old with the following criteria may be eligible: ECOG performance status 0 or 1; the tumor must be unilateral-invasive adenocarcinoma of the breast on histologic examination; HER2 status must indicate that the tumor is HER2-low; the patient must have undergone either a total mastectomy or breast-conserving surgery (lumpectomy). Additional requirements are in the protocol

Purpose

The main purpose of this study is to learn if adding a targeted therapy, trastuzumab, to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning.

Enrollment

(708) 327-3102

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.